Study to assess the tolerability and durable effect of AMG 145 in patients with Hyperlipidemia To evaluate the effect of 52 weeks of subcutaneous (SC) AMG 145 monthly (QM), compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) when added to backgr...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A clinical study to assess the safety, tolerability and efficacy of AMG 145 in subjects with homozygous familial hypercholesterolemia Part A: To characterize the effect of 12 weeks of subcutaneous (SC) AMG 145 on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in subjects with homozygous familial hypercho...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double Blinded, Multi-Center Study 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination with AMG 386 or Placebo in Subjects with Metastatic Clear Cell Carcinoma of the Kidney To estimate the clinical benefit as measured by progression free survival (PFS) of subjects receiving AMG 386 (either 3mg/kg or 10mg/kg IV QW) in combination with sorafenib (400mg PO BID) compared to ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2, Randomized, Double Blind, Placebo- Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Chemotherapy- Induced Thrombocytopenia in Subjects With Advanced Non- Small Cell Lung Cancer Already Receiving Gemcitabine and Platinum To evaluate the safety of AMG 531 in treating CIT in NSCLC subjects receiving myelosuppressive chemotherapy.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study designed to evaluate the safety and efficacy of AMG 145, in people with elevated LDL-C and not treated with any other lipid-lowering medications.To do this, AMG 145 will be compared with placebo and with ezetimibe Primary objective: To evaluate the effect of 12 weeks of subcutaneous (SC) AMG 145 monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baselin...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) To assess the effect of anemia therapy with darbepoetin alfa on the composite event comprising all-cause mortality and cardiovascular (CV) events (including myocardial ischemia, congestive heart failu...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women with Low Bone Mineral Density The primary objective is to evaluate the effect of denosumab 60 mg q 6 months on total hip bone mineral density (BMD) at 12 months in postmenopausal women with low BMD previously treated with alendron...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study to access whether AMG 145, in people with dyslipidemia, who cannot tolerate an effective dose of a statin, causes any side effects and to confirm that treatment with AMG 145 will lower LDL-cholesterol and increase HDL-cholesterol. To do this, AMG 145 will be compared with ezetimibe which is a cholesterol-lowering medication used to help patients manage cholesterol levels To evaluate the effect of 12 weeks of subcutaneous (SC) AMG 145 every 2 weeks (Q2W) and monthly (QM), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (L...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacy and Safety Study of Romiplostim in Paediatrics with Immune Thrombocytopenia The primary objective is to describe the percentage of time that pediatric subjects with immune thrombocytopenia (ITP) have a platelet response in the first 6 months from the start of treatment with r...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double-Blind, Placebo-controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer To determine the treatment effect of AMG 162 compared with placebo on lumbar spine bone mineral density (BMD) in men with nonmetastatic prostate cancer undergoing ADT.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune